China – Conditional OK for Sinopharm’s COVID-19 vaccine

China’s state-owned pharmaceutical company Sinopharm has scored approval from Chinese health authorities after reporting a 79% efficacy rate in phase 3 trials.

The vaccine has been granted a conditional marketing approval, after 60,000 volunteers took part in phase 3 clinical trials across China, UAE and Bahrain.

Last week, the company said that the vaccine’s ‘protective efficacy’ against COVID-19 was 79.34%, slightly less than the previously reported efficacy rate of 86% in UAE.

In a separate statement, published on 2 January, Sinopharm added that “because the standards of diagnosis of infection cases and review process of phase 3 clinical trials vary in different countries, the 86% efficacy rate announced by UAE and 79.34% by China are both real and valid”…